Durability and On-Treatment Predictors of Recompensation in Entecavir-Treated Patients with Hepatitis B and Decompensated Cirrhosis

You Deng,Haiyan Kang,Huiling Xiang,Yuemin Nan,Jinhua Hu,Qinghua Meng,Hong Zhao,Qi Wang,Jilian Fang,Jie Xu,Xiaoming Wang,Calvin Q. Pan,Hong You,Xiaoyuan Xu,Wen Xie,Jidong Jia

DOI: https://doi.org/10.1016/j.jhepr.2024.101091

IF: 9.917

2024-01-01

JHEP Reports

Abstract:Background & AimsHepatic recompensation may be achieved in patients with decompensated cirrhosis due to chronic hepatitis B (CHB) upon effective suppression of viral replication by nucleos(t)ide analogues. However, the optimal timing and predictors for recompensation and the subsequent clinical course of CHB patients with vs. without recompensation are not well-defined.MethodsThis study was a retrospective extension of a multi-centre prospective cohort, focusing on CHB patients with decompensated cirrhosis treated with entecavir. We followed patients beyond treatment week 120 until a second decompensation event or June 2023. We identified the optimal timing and predictors for recompensation by week 120, evaluated durability of recompensation in patients fulfilling recompensation criteria by week 120 and examined late recompensation in those who did not fulfill it by week 120.Results resultsAt treatment week 24, a serum albumin ≥34g/L predicted recompensation by week 120. The Brec-PAS model offered good predictability for recompensation by week 120. Of the 283 patients who finished 120 weeks of therapy, 175 were followed beyond week 120 (median follow-up: 240 weeks). Among the 106 patients achieving recompensation by week 120, 92 (86.8%) maintained recompensation for another 120 (72-168) weeks. Among the 69 patients without recompensation by week 120, 40.6% attained late recompensation during the subsequent 120 (72-168) weeks. Additionally, HCC incidence was lower in recompensated group (5.0% vs. 16.13%, p = 0.002).ConclusionsA serum albumin ≥34g/L at treatment week 24 predicts recompensation by week 120. Recompensation achieved by week 120 of NA treatment is maintained in >80% of patients on the long-term. Some patients may achieve recompensation only after >120 weeks of NA treatment. HCC incidence was reduced but not completely abolished after achieving recompensation.